



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 11:54  
**Last Report Issued** 08/01/2008 06:42

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 1280SP-POS  
**Patient ID** 1280SP-POS  
**Chain 1**  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 08001896  
**Received** 07/15/2008 10:43

**Sample ID** 08001896-001  
**Matrix** Serum or Plasma  
**Patient Name** 1280SP-POS  
**Patient ID** 1280SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**1280SP Clorazepate as Metabolite, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Nordiazepam	5000	ng/mL	20	ELEVATED
Synonym(s): Clorazepate Metabolite				
Mean steady-state plasma concentrations during chronic daily therapy with 50 mg of Clorazepate: 1600 ng/mL (range, 1200 - 2600 ng/mL)				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.